Skip to main content
Contact Us
Subscribe
E-Edition
82°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Amneal Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
August 20, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Second Quarter 2024 Financial Results
August 09, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
August 07, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
July 29, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Report Second Quarter 2024 Results on August 9, 2024
July 11, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
July 09, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
July 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Releases 2023 Environmental, Social and Governance Report
June 28, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
June 05, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
May 22, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at Upcoming Investor Conference
May 22, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports First Quarter 2024 Financial Results
May 03, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
April 24, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
April 16, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Report First Quarter 2024 Results on May 3, 2024
April 10, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
March 28, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
March 25, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
March 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
February 27, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at Upcoming Investor Conference
February 13, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
January 31, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
January 10, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
January 04, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Announces Move to Nasdaq
December 15, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
December 07, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
December 01, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at Upcoming Investor Conferences
November 03, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
October 23, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.